

**ALTERATIONS OF MICRORNA EXPRESSION PATTERNS IN  
HUMAN CERVICAL CARCINOMA CELLS (CA SKI) TOWARDS  
1'S-1'-ACETOXYCHAVICOL ACETATE (ACA) AND  
CISPLATIN (CDDP)**

**PHUAH NEOH HUN**

**FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2012**

**ALTERATIONS OF MICRORNA EXPRESSION  
PATTERNS IN HUMAN CERVICAL CARCINOMA  
CELLS (CA SKI) TOWARDS  
1'S-1'-ACETOXYCHAVICOL ACETATE (ACA)  
AND CISPLATIN (CDDP)**

**PHUAH NEOH HUN**

**DISSERTATION SUBMITTED IN FULFILLMENT OF  
THE REQUIREMENTS FOR THE DEGREE OF  
MASTER OF SCIENCE**

**INSTITUTE OF BIOLOGICAL SCIENCES  
FACULTY OF SCIENCE  
UNIVERSITY OF MALAYA  
KUALA LUMPUR**

**2012**

UNIVERSITI MALAYA

**ORIGINAL LITERARY WORK DECLARATION**

Name of Candidate: PHUAH NEOH HUN (I.C/Passport No: 860215-07-5393)

Registration/Matric No: SGR090093

Name of Degree: MASTER OF SCIENCE

Title of Project Paper/Research Report/Dissertation/Thesis ("this Work"): ALTERATIONS OF MICRORNA EXPRESSION PATTERNS IN HUMAN CERVICAL CARCINOMA CELLS (CA SKI) TOWARDS 1'S-1'-ACETOXYCHAVICOL ACETATE (ACA) AND CISPLATIN (CDDP)

Field of Study: MOLECULAR ONCOLOGY

I do solemnly and sincerely declare that:

- (1) I am the sole author/writer of this Work;
- (2) This Work is original;
- (3) Any use of any work in which copyright exists was done by way of fair dealing and for permitted purposes and any excerpt or extract from, or reference to or reproduction of any copyright work has been disclosed expressly and sufficiently and the title of the Work and its authorship have been acknowledged in this Work;
- (4) I do not have any actual knowledge nor do I ought reasonably to know that the making of this work constitutes an infringement of any copyright work;
- (5) I hereby assign all and every rights in the copyright to this Work to the University of Malaya ("UM"), who henceforth shall be owner of the copyright in this Work and that any reproduction or use in any form or by any means whatsoever is prohibited without the written consent of UM having been first had and obtained;
- (6) I am fully aware that if in the course of making this Work I have infringed any copyright whether intentionally or otherwise, I may be subject to legal action or any other action as may be determined by UM.

  
Candidate's Signature

Date: 06/08/12

Subscribed and solemnly declared before,

  
Witness's Signature

Name: Noor Hasima Bt. Nagoor PhD  
Designation: Associate Professor  
Division of Genetics & Molecular Biology  
Institute of Biological Sciences  
Faculty of Science  
University of Malaya  
50603 Kuala Lumpur, Malaysia

Date: 6 . 8 . 12

## ABSTRACT

The main aims of this study were to investigate the combined effects of a natural compound 1'S-1'-acetoxychavicol acetate (ACA) with cisplatin (CDDP) on human cervical carcinoma cells Ca Ski, and to identify microRNAs (miRNAs) associated with response towards ACA and/or CDDP. Data obtained from MTT cell viability assays indicated that both ACA and CDDP induced dose- and time-dependent cytotoxicity on Ca Ski cells when used as a standalone agent. The *in vitro* studies also demonstrated that ACA potentiates the cytotoxic effects of CDDP when used in combination through synergistic interactions. The miRNA microarray was used to identify global miRNA expression profiles on Ca Ski cells following administration of ACA and/or CDDP, and it was found that 25 miRNAs were differentially expressed in response towards ACA and/or CDDP with markedly different pattern of miRNA expressions between different treatment regimens. Three promising miRNA candidates (hsa-miR-138, hsa-miR-210 and hsa-miR-744) which exhibited the highest fold-change in combination chemotherapy and whose expressions were among those validated by qRT-PCR, were selected for bioinformatic analyses. The hypothetical pathway model comprising interaction between candidate miRNAs with their putative target genes indicated that the cytotoxic effects induced by ACA in combination with CDDP may be regulated by miRNA expression. Therefore, our study provides a platform for potential therapeutic approaches in chemotherapy, whereby miRNA expression can be exploited to further improve efficacy in combination chemotherapy.

## ABSTRAK

Tujuan utama penyelidikan ini adalah untuk menyiasat kesan gabungan kompaun semulajadi 1'S-1'-acetoxychavicol acetate (ACA) dengan cisplatin (CDDP) ke atas sel-sel karsinoma serviks manusia Ca Ski, serta mengenal pasti miRNA yang bertindak balas terhadap rawatan ACA dan/atau CDDP. Data yang diperolehi daripada eksperimen MTT menunjukkan bahawa ACA dan CDDP menyebabkan sitotoksik yang bergantung pada dos dan tempoh rawatan apabila digunakan sebagai ejen 'standalone'. Selain itu, kajian *in vitro* juga menunjukkan bahawa ACA mempotensikan kesan sitotoksik CDDP melalui hubungan sinergistik apabila digabungkan. MiRNA microarray digunakan untuk mengenal pasti profil ekspresi global miRNA setelah dirawat dengan ACA dan/atau CDDP, dan didapati bahawa terdapat sebanyak 25 miRNA yang diekspreskan secara berlainan apabila dirawat dengan ACA dan/atau CDDP dengan corak ekspresi miRNA yang berbeza antara regimen rawatan yang berlainan. Tiga calon miRNA yang menjanjikan (hsa-miR-138, hsa-miR-210 and hsa-miR-744), yang merupakan antara beberapa miRNA yang disahkan ekspresinya dengan qRT-PCR, dipilih untuk analisis bioinformatik kerana mereka mempamerkan 'fold-change' yang paling tinggi dalam kemoterapi kombinasi. 'Hypothetical pathway model' yang melibatkan interaksi miRNA dengan target gen putatif miRNA menunjukkan bahawa kesan-kesan sitotoksik yang ditunjukkan oleh ACA dan/atau CDDP berkemungkinan besar disebabkan oleh ekspresi miRNA. Maka, kajian kami menyediakan satu platform bagi pendekatan terapeutik dalam kemoterapi, dimana ekspresi miRNA boleh dimanipulasikan untuk meningkatkan efikasi dalam kemoterapi kombinasi.

## ACKNOWLEDGEMENT

First of all, I would like to express my deepest appreciation to my project supervisor, Associate Professor Dr. Noor Hasima Nagoor, for her support and guidance in helping me to complete my project successfully.

I am indebted to Dr. Lionel In Lian Aun for his willingness to share his vast expertise and knowledge with me. I am also thankful to my fellow lab mates from Cancer Research Laboratory in BGM2 for lending me a helping hand whenever needed, and also in making this an invaluable experience for me.

I am grateful to Professor Dr. Khalijah Awang and Mr. Mohamad Nurul Azmi from Centre for Natural Product Research and Drug Discovery (CENAR) for providing 1'S-1'-acetoxychavicol acetate (ACA), without which this research project would not possible. Special thanks to Oral Cancer Research and Coordinating Centre (OCRCC) for allowing me to use their software to analyze my microRNA microarray results.

I would like to acknowledge and thank University of Malaya for their generosity in financing this research project through University of Malaya Postgraduate Research Grant (PPP) (PS240-2009C and PV044-2011B) and University of Malaya Research Grant (UMRG) (RG037-10BIO). I am also grateful to University of Malaya for sponsoring my studies through the University of Malaya Fellowship Scheme.

Last but not least, I would also like to thank my family and friends for their constant love, care and support throughout this duration as well as everyone else who has played a part in completion of this research project.

## TABLE OF CONTENTS

	Page No.
<b>Abstract</b>	ii
<b>Abstrak</b>	iii
<b>Acknowledgement</b>	iv
<b>Table of contents</b>	v
<b>List of Figures</b>	ix
<b>List of Tables</b>	ix
<b>List of Abbreviations</b>	xii
<b>Chapter 1: Introduction</b>	1
1.1 Study objectives	4
<b>Chapter 2: Literature review</b>	5
2.1 Cancer	
2.1.1 Overview	5
2.1.2 Multistep carcinogenesis	6
2.2 Cervical cancer	
2.2.1 Overview	8
2.2.2 Cervical cancer subtypes	8
2.2.3 Etiology of cervical cancers	9
2.2.4 Cervical carcinogenesis	10
2.2.5 Grading in cervical cancer	11
2.2.6 Staging of cervical cancer	11
2.2.7 Epidemiology in cervical cancer	12
2.2.8 Human epidermoid cervical carcinoma Ca Ski	13

2.3	Cell cycle	
2.3.1	Overview	14
2.3.2	Cell cycle regulation	14
2.3.3	Cell cycle and cancer	17
2.4	Cell death	
2.4.1	Overview	19
2.4.2	Apoptosis	19
2.4.3	Apoptosis and cancer	21
2.5	Chemotherapy	
2.5.1	Overview	23
2.5.2	Drug resistance	24
2.5.3	Combination therapy	25
2.5.4	Combination analysis	26
2.5.5	Cisplatin	28
2.6	Natural compounds as anti-cancer agents	
2.6.1	Overview	30
2.6.2	Plant derived anti-cancer agents	30
2.6.3	1'S-1'-acetoxychavicol acetate	31
2.7	MicroRNAs	
2.7.1	Overview	33
2.7.2	Naming conventions for miRNAs	34
2.7.3	Biogenesis of miRNAs	35
2.7.4	MiRNAs and chemotherapy	37
	<b>Chapter 3: Materials and methods</b>	<b>38</b>
3.1	1'S-1'-acetoxychavicol acetate (ACA) and cisplatin (CDDP)	
3.1.1	1'S-1'-acetoxychavicol acetate (ACA)	38
3.1.2	Cisplatin (CDDP)	38



3.2	Cell cultures	
3.2.1	Cell lines and culture conditions	39
3.2.2	Subculturing monolayer cell lines	38
3.2.3	Cryopreservation of cell lines	40
3.2.4	Thawing of cryopreserved cell lines	41
3.2.5	Cell count	41
3.3	MTT cell viability assays	42
3.4	Total RNA extraction and quality control	
3.4.1	Total RNA extraction	43
3.4.2	RNA quality control	
3.4.2.1	RNA analysis using UV spectrophotometry	44
3.4.2.2	RNA analysis using Agilent RNA 6000 Nano Kit	45
3.5	MiRNA microarray	
3.5.1	FlashTag™ RNA labeling	46
3.5.2	ELOSA quality control assays	47
3.5.3	Hybridization of Affymetrix arrays	48
3.5.4	Washing and staining of Affymetrix arrays	49
3.5.5	Statistical and miRNA expression analysis	49
3.6	Validation of miRNA microarray data	
3.6.1	Reverse transcription PCR	50
3.6.2	Real-time PCR amplification and quantitation	50
3.7	Bioinformatic analyses of miRNA gene targets	51
3.8	Statistical analysis	51
	<b>Chapter 4: Results</b>	<b>52</b>
4.1	Cytotoxicity assays	
4.1.1	Cytotoxic effects of ACA and CDDP on Ca Ski cells	52
4.1.2	Cytotoxic effects of ACA in combination with CDDP on Ca Ski cells	53

4.2	Combination analysis	56
4.3	Normal cells and solvent control	
4.3.1	Cytotoxic effects of ACA and CDDP on normal cells	58
4.3.2	Cytotoxic effects of DMSO on various cell lines	60
4.4	RNA quality control	61
4.5	MiRNA expression on Ca Ski cells	
4.5.1	MiRNA microarray	62
4.5.2	Validation by qRT-PCR	63
4.5.3	Correlation between miRNA microarray data and qRT-PCR data	65
4.6	Bioinformatic analyses of miRNA gene targets	65
	<b>Chapter 5: Discussion</b>	67
5.1	Cytotoxic effects of ACA and/or CDDP	67
5.2	Alterations in miRNAs expression patterns by ACA and/or CDDP	69
5.3	Interaction between candidate miRNAs with their putative target genes	71
5.4	Future research	76
	<b>Chapter 6: Conclusion</b>	77
	<b>References</b>	78
	<b>Appendices</b>	99
	Appendix 1: Solutions, formulations and commercial kits	99
	Appendix 2: MTT assays on Ca Ski cells for standalone ACA	102
	Appendix 3: MTT assays on Ca Ski cells for standalone CDDP	103
	Appendix 4: MTT assays on Ca Ski cells for ACA in combination with CDDP	104
	Appendix 5: MTT assays on NP69 cells for standalone ACA	105
	Appendix 6: MTT assays on NP69 cells for standalone CDDP	105
	Appendix 7: MTT assays on NP69 cells for ACA in combination with CDDP	105
	Appendix 8: Predicted gene targets using TargetScanHuman v5.2	106

## LIST OF FIGURES

		Page No.
Figure 2.1	Comparison between cell division in normal cells and cancer cells	6
Figure 2.2	Multistep carcinogenesis	7
Figure 2.3	Cervical carcinogenesis	10
Figure 2.4	Cell cycle regulation	15
Figure 2.5	Apoptotic pathways	21
Figure 2.6	Mechanisms of drug resistance in cancer cells	25
Figure 2.7	Chemical structure of cisplatin (CDDP)	28
Figure 2.8	Chemical structure of 1'S-1'-acetoxychavicol acetate (ACA)	31
Figure 2.9	Biogenesis of microRNAs	36
Figure 3.1	Chemical structure of 1'S-1'-acetoxychavicol acetate (ACA)	38
Figure 3.2	Chemical structure of cisplatin (CDDP)	38
Figure 4.1	Comparative dose-response curve for standalone ACA on Ca Ski cells at various concentrations and incubation hours	53
Figure 4.2	Comparative dose-response curve for standalone CDDP on Ca Ski cells at various concentrations and incubation hours	53
Figure 4.3	Comparative dose-response curve for ACA and CDDP on Ca Ski cells for different combinations following 24 h exposure	55
Figure 4.4	Isobologram analysis of ACA in combination with CDDP	57
Figure 4.5	Comparative dose-response curve at various concentrations of standalone ACA (0 - 12.0 $\mu$ M) and CDDP (0 - 200.0 $\mu$ M) on NP69 cells following 24 h exposure.	59
Figure 4.6	Comparative dose-response curve for ACA in combination with CDDP on NP69 cells following 24 h exposure	59

Figure 4.7	Cytotoxic effects of DMSO at 1.2% (v/v) on Ca Ski and NP69 cells following 24 h exposure	60
Figure 4.8	Normalized fold expression for hsa-miR-138, hsa-miR-210, hsa-miR-224 and hsa-miR-744	64
Figure 4.9	Correlation between miRNA microarray data and qRT-PCR data	65
Figure 4.10	Pathway model comprising of interaction between candidate miRNAs with their putative target genes	66

## LIST OF TABLES

	Page No.	
Table 2.1	FIGO staging of cervical carcinomas	12
Table 2.2	Cyclin-dependent kinase inhibitor (CKI) proteins	16
Table 3.1	Summary of experimental setup used in this study indicating treatment groups with biological replicates	44
Table 3.2	Setup for FlashTag™ RNA labeling	46
Table 3.3	Setup for hybridization solution for ELOSA quality control assays	48
Table 3.4	Setup for array hybridization cocktail	48
Table 3.5	Summary of washing and staining protocol for each array	49
Table 3.6	PCR setup for reverse transcription PCR	50
Table 3.7	PCR setup for real-time PCR amplification and quantitation	51
Table 4.1	Summary of combination regimens employed for MTT cell viability assay to evaluate the combined effects of ACA and CDDP on Ca Ski cells.	55
Table 4.2	Summary of IC <sub>50</sub> values for standalone ACA, standalone CDDP and ACA in combination with CDDP at various concentrations following 24 h exposure	56
Table 4.3	Combination index analysis of ACA in combination with CDDP	58
Table 4.4	RNA analysis using UV spectrophotometry	61
Table 4.5	RNA analysis using Agilent RNA 6000 Nano Kit	62
Table 4.6	List of miRNA expression fold-change alterations following the administration of ACA and/or CDDP on Ca Ski cells over 2 h	63

## LIST OF ABBREVIATIONS

3' UTR	Three prime untranslated region
5' UTR	Five prime untranslated region
%	Percentage
×	Times
°C	Degree Celsius
μ	Micro
μg	Microgram
μg/ml	Microgram per militre
μl	Microlitre
μM	Micromolar
®	Registered
(v/v)	Volume per volume
(w/v)	Weight per volume
A	Absorbance
ASR	Age-standardized incidence rate
ATP	Adenosine triphosphate
Bfl-1/A1	Bcl-2-related protein A1
ACA	1'S-1'-acetoxychavicol acetate
AIF	Apoptosis inducing factor
Apaf-1	Apoptotic protease-activating factor-1
ATM	Ataxia-telangiectasia-mutated
Bad	Bcl-2-agonist death promoter
Bax	Bcl-2 associated X protein
Bcl-2	B-cell lymphoma 2

Bcl-xL	B-cell lymphoma-extra large
bp	Base pairs
BSA	Bovine serum albumin
cAMP	Cyclic adenosine monophosphate
CARIF	Cancer Research Initiative Foundation
Caspase	Cysteine aspartate protease
CaV	Voltage-gated calcium channels
CBP	CREB-binding protein
CDC	Cell-division cycle
CDDP	Cisplatin
CDK	Cyclin-dependent kinase
cDNA	Complimentary deoxyribonucleic acid
CI	Combination index
CIN	Cervical intraepithelial neoplasia
CKI	Cyclin-dependent kinase inhibitor
cm	Centimeter
cm <sup>2</sup>	Centimeter square
CO <sub>2</sub>	Carbon dioxide
CREB	cAMP response element-binding
DAVID	Database for Annotation, Visualization and Integrated Discovery
DEPC	Diethylpyrocarbonate
dH <sub>2</sub> O	Distilled water
DISC	Death-inducing signaling complex
DMEM	Dulbecco's Modified Eagle Medium
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid

DNase	Deoxyribonuclease
dNTP	Deoxy-nucleoside-triphosphate
DR	Death receptor
Dsh	Dishevelled
EDTA	Ethylenediaminetetraacetic acid
ELOSA	Enzyme Linked Oligosorbent Assay
ERK	Extracellular signal-regulated protein kinase
et al	And others
FADD	Fas-associated death domain
FAK	Focal adhesion kinase
FDA	Food and Drug Administration
FBS	Fetal bovine serum
FIGO	Fédération of Internationale de Gynécologie et d'Obstétrique
FLIP	FLICE-like inhibitory protein
Fzd	Frizzled
<i>g</i>	Gravity
<i>g</i>	Gram
GSH	Glutathione
<i>h</i>	Hour
hCG	Human chorionic gonadotropin
HCl	Hydrochloric acid
HIF	Hypoxia-inducible factor
HPV	Human papillomavirus
HSV-2	Herpes simplex virus-2
IACR	International Agency for Research on Cancer
IAP	Inhibitor of apoptotic protein



IC <sub>50</sub>	50% inhibitory concentration
ICO	Institut Català d'Oncologia
IGF	Insulin growth factor
IKK	I $\kappa$ B kinase
IL-3	Interleukin-3
Inc.	Incorporated
JNK	c-Jun N-terminal kinases
kDA	Kilo Dalton
KEGG	Kyoto Encyclopedia of Genes and Genomes
kg	Kilogram
KSFM	Keratinocyte serum-free medium
LEF	Lymphoid enhancer factor
M	Molar
MAPK	Mitogen-activated protein kinase
MEK	MAPK kinase
mg	Milligram
mg/ml	Milligram per millitre
MgCl <sub>2</sub>	Magnesium chloride
min	Minute
miRNA	Micro ribonucleic acid
ml	Milliliter
mm	Millimetre
mM	Millimolar
MnCl <sub>2</sub>	Manganese chloride
mRNA	Messenger ribonucleic acid
MPT	Mitochondrial permeability transition

MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide
NCI	National Cancer Institute
NCR	National Cancer Registry
NCX	Sodium-calcium exchanger
NF- $\kappa$ B	Nuclear factor kappa B
ng	Nanogram
nm	Nanometer
nM	Nanomolar
p53	Protein 53
Pap	Papanicolaou
PBS	Phosphate buffered saline
PDGF	Platelet-derived growth factor
PDGFR	Platelet-derived growth factor receptor
pH	Potential of hydrogen
PI3K	Phosphoinositide 3-kinase
PMCA	Plasma membrane Ca <sup>2+</sup> ATPase
pRb	Retinoblastoma protein
psi	Pound force per square inch
<i>r</i>	Pearson correlation coefficient
RIN	RNA Integrity Number
RIP	Receptor interacting protein
RISC	RNA-induced silencing complex
RMA	Robust Multichip Average
RNA	Ribonucleic acid
RNase	Ribonuclease
ROC	Receptor-operated calcium channels

rpm	Revolutions per minute
rRNA	Ribosomal ribonucleic acid
S	Svedberg
s	Second
SA-HRP	Streptavidin-horseradish peroxidase
SD	Standard deviation
SDS	Sodium dodecyl sulfate
SOS	Son of sevenless
SSC	Saline sodium citrate
TCF	T-cell factor
TGF- $\beta$	Transforming growth factor- $\beta$
™	Trademark
TMB	3,3',5,5'-Tetramethylbenzidine
TNF	Tumor necrosis factor
TNFR	Tumor necrosis factor receptor
TRADD	Tumor necrosis factor receptor associated death domain
TRAF2	Tumor necrosis factor receptor-associated factor 2
U	Unit
USA	United States of America
UV	Ultraviolet
WHO	World Health Organization
WNT	Wingless-type MMTV integration site family